Selected research
Industry Research
Psoriasis Biosimilar Industry Research Report 2026
Market perspective
The global Psoriasis Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Psoriasis Biosimilar market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Psoriasis Biosimilar market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Psoriasis Biosimilar market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Psoriasis Biosimilar include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Psoriasis Biosimilar market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Psoriasis Biosimilar.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Psoriasis Biosimilar Market by Company
Amgen Inc
Celltrion
Coherus BioSciences
Fresenius Kabi
GenScript
Gyros Protein Technologies AB
Hoffmann-La Roche Ltd
Novartis International AG
Reddy's Laboratories
Samsung Bioepis
Samsung Bioepis Co., Ltd.
Viatris
Pfizer Inc.
Merck KGaA
Sandoz
Psoriasis Biosimilar Segment by Type
TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Other Biosimilars
Psoriasis Biosimilar Segment by Application
Plaque Psoriasis
Psoriatic Arthritis
Other
Psoriasis Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Psoriasis Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- Other Biosimilars
Applications
- Plaque Psoriasis
- Psoriatic Arthritis
- Other
Companies covered
- Amgen Inc
- Celltrion
- Coherus BioSciences
- Fresenius Kabi
- GenScript
- Gyros Protein Technologies AB
- Hoffmann-La Roche Ltd
- Novartis International AG
- Reddy's Laboratories
- Samsung Bioepis
- Samsung Bioepis Co., Ltd.
- Viatris
- Pfizer Inc.
- Merck KGaA
- Sandoz
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Psoriasis Biosimilar by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- 2.2.3 Other Biosimilars
- 2.3 Psoriasis Biosimilar by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Plaque Psoriasis
- 2.3.3 Psoriatic Arthritis
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Psoriasis Biosimilar Breakdown Data by Type
- 3.1 Global Psoriasis Biosimilar Historic Market Size by Type (2021-2026)
- 3.2 Global Psoriasis Biosimilar Forecasted Market Size by Type (2027-2032)
4 Psoriasis Biosimilar Breakdown Data by Application
- 4.1 Global Psoriasis Biosimilar Historic Market Size by Application (2021-2026)
- 4.2 Global Psoriasis Biosimilar Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Psoriasis Biosimilar Market Perspective (2021-2032)
- 5.2 Global Psoriasis Biosimilar Growth Trends by Region
- 5.2.1 Global Psoriasis Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Psoriasis Biosimilar Historic Market Size by Region (2021-2026)
- 5.2.3 Psoriasis Biosimilar Forecasted Market Size by Region (2027-2032)
- 5.3 Psoriasis Biosimilar Market Dynamics
- 5.3.1 Psoriasis Biosimilar Industry Trends
- 5.3.2 Psoriasis Biosimilar Market Drivers
- 5.3.3 Psoriasis Biosimilar Market Challenges
- 5.3.4 Psoriasis Biosimilar Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Psoriasis Biosimilar Players by Revenue
- 6.1.1 Global Top Psoriasis Biosimilar Players by Revenue (2021-2026)
- 6.1.2 Global Psoriasis Biosimilar Revenue Market Share by Players (2021-2026)
- 6.2 Global Psoriasis Biosimilar Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Psoriasis Biosimilar Head Office and Area Served
- 6.4 Global Psoriasis Biosimilar Players, Product Type & Application
- 6.5 Global Psoriasis Biosimilar Manufacturers Established Date
- 6.6 Global Psoriasis Biosimilar Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Psoriasis Biosimilar Market Size (2021-2032)
- 7.2 North America Psoriasis Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Psoriasis Biosimilar Market Size by Country (2021-2026)
- 7.4 North America Psoriasis Biosimilar Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Psoriasis Biosimilar Market Size (2021-2032)
- 8.2 Europe Psoriasis Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Psoriasis Biosimilar Market Size by Country (2021-2026)
- 8.4 Europe Psoriasis Biosimilar Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Psoriasis Biosimilar Market Size (2021-2032)
- 9.2 Asia-Pacific Psoriasis Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Psoriasis Biosimilar Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Psoriasis Biosimilar Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Psoriasis Biosimilar Market Size (2021-2032)
- 10.2 South America Psoriasis Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Psoriasis Biosimilar Market Size by Country (2021-2026)
- 10.4 South America Psoriasis Biosimilar Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Psoriasis Biosimilar Market Size (2021-2032)
- 11.2 Middle East & Africa Psoriasis Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Psoriasis Biosimilar Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Psoriasis Biosimilar Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Amgen Inc
- 12.1.1 Amgen Inc Company Information
- 12.1.2 Amgen Inc Business Overview
- 12.1.3 Amgen Inc Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
- 12.1.5 Amgen Inc Recent Developments
- 12.2 Celltrion
- 12.2.1 Celltrion Company Information
- 12.2.2 Celltrion Business Overview
- 12.2.3 Celltrion Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
- 12.2.5 Celltrion Recent Developments
- 12.3 Coherus BioSciences
- 12.3.1 Coherus BioSciences Company Information
- 12.3.2 Coherus BioSciences Business Overview
- 12.3.3 Coherus BioSciences Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
- 12.3.5 Coherus BioSciences Recent Developments
- 12.4 Fresenius Kabi
- 12.4.1 Fresenius Kabi Company Information
- 12.4.2 Fresenius Kabi Business Overview
- 12.4.3 Fresenius Kabi Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
- 12.4.5 Fresenius Kabi Recent Developments
- 12.5 GenScript
- 12.5.1 GenScript Company Information
- 12.5.2 GenScript Business Overview
- 12.5.3 GenScript Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.5.4 GenScript Psoriasis Biosimilar Product Portfolio
- 12.5.5 GenScript Recent Developments
- 12.6 Gyros Protein Technologies AB
- 12.6.1 Gyros Protein Technologies AB Company Information
- 12.6.2 Gyros Protein Technologies AB Business Overview
- 12.6.3 Gyros Protein Technologies AB Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
- 12.6.5 Gyros Protein Technologies AB Recent Developments
- 12.7 Hoffmann-La Roche Ltd
- 12.7.1 Hoffmann-La Roche Ltd Company Information
- 12.7.2 Hoffmann-La Roche Ltd Business Overview
- 12.7.3 Hoffmann-La Roche Ltd Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
- 12.7.5 Hoffmann-La Roche Ltd Recent Developments
- 12.8 Novartis International AG
- 12.8.1 Novartis International AG Company Information
- 12.8.2 Novartis International AG Business Overview
- 12.8.3 Novartis International AG Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
- 12.8.5 Novartis International AG Recent Developments
- 12.9 Reddy's Laboratories
- 12.9.1 Reddy's Laboratories Company Information
- 12.9.2 Reddy's Laboratories Business Overview
- 12.9.3 Reddy's Laboratories Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
- 12.9.5 Reddy's Laboratories Recent Developments
- 12.10 Samsung Bioepis
- 12.10.1 Samsung Bioepis Company Information
- 12.10.2 Samsung Bioepis Business Overview
- 12.10.3 Samsung Bioepis Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
- 12.10.5 Samsung Bioepis Recent Developments
- 12.11 Samsung Bioepis Co., Ltd.
- 12.11.1 Samsung Bioepis Co., Ltd. Company Information
- 12.11.2 Samsung Bioepis Co., Ltd. Business Overview
- 12.11.3 Samsung Bioepis Co., Ltd. Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
- 12.11.5 Samsung Bioepis Co., Ltd. Recent Developments
- 12.12 Viatris
- 12.12.1 Viatris Company Information
- 12.12.2 Viatris Business Overview
- 12.12.3 Viatris Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.12.4 Viatris Psoriasis Biosimilar Product Portfolio
- 12.12.5 Viatris Recent Developments
- 12.13 Pfizer Inc.
- 12.13.1 Pfizer Inc. Company Information
- 12.13.2 Pfizer Inc. Business Overview
- 12.13.3 Pfizer Inc. Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
- 12.13.5 Pfizer Inc. Recent Developments
- 12.14 Merck KGaA
- 12.14.1 Merck KGaA Company Information
- 12.14.2 Merck KGaA Business Overview
- 12.14.3 Merck KGaA Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
- 12.14.5 Merck KGaA Recent Developments
- 12.15 Sandoz
- 12.15.1 Sandoz Company Information
- 12.15.2 Sandoz Business Overview
- 12.15.3 Sandoz Revenue in Psoriasis Biosimilar Business (2021-2026)
- 12.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
- 12.15.5 Sandoz Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst